Close
Close
Treatment Database
Ambrisentan
Trade Name Volibris
Orphan Indication Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
EU Market Approval 24-04-2008
EU Designation Date 11-04-2005
Sponsor Glaxo Group Ltd
More about Pulmonary Arterial Hypertension
Free Newsletter
Treatment News
Related Videos